. Author manuscript; available in PMC: 2025 Jun 1.

Published in final edited form as: Pediatr Infect Dis J. 2024 Feb 12;43(6):520–524. doi: 10.1097/INF.0000000000004278

Table 1:

Demographics and Baseline Characteristics

		All Courses (n=71)	CIV Courses that Achieved a Therapeutic Concentration (n=54)
Age; median (range)		4.5 years (0.4 – 20 years)	4.9 years (0.4 – 15 years)
Gender; n (%)	Male	37 (52.1)	26 (48.1)
Race; n (%)	White Black Other	55 (77.5) 12 (16.9) 4 (5.6)	43 (79.6) 8 (14.8) 3 (5.6)
Primary Diagnosis; n (%)	Leukemia/Lymphoma Solid Tumor/Neuro-Onc Non-malignant Hematology	31 (43.7) 37 (52.1) 3 (4.2)	23 (42.6) 29 (53.7) 2 (3.7)
Prior Transplant; n (%)		18 (25.4)	14 (25.9)
Switched from Intermittent Vancomycin; n (%)		67 (94.4%)	54 (100%)